Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Viking Therapeutics, Inc. (VKTX)
USD38.12
-0.74 (-1.90%)
US NASDAQ Healthcare Biotechnology
Address
9920 Pacific Heights Boulevard 92121
San Diego, CA, US
San Diego, CA, US
CEO
Brian Lian
Website
vikingtherapeutics.com
IPO
2015-04-28
CIK 1607678 ISIN US92686J1060
Also trades on
London Stock Exchange · 0VQA.L (USD)
NASDAQ Capital Market · VKTX (USD)
Description
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
News Sentiment (7d)
13 articles
- 3 High Growth GLP-1 Biotech Winners to Buy in July 24/7 Wall Street
- Is This Biotech Stock a Buy After Its Massive Rally? The Motley Fool
- Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? Fool - Investing News
- Chip Rout Drags Nasdaq 100 Lower, Oil Climbs: Stock Market Today Benzinga
- Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD38.12
-0.74 (-1.90%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.68
Float Shares
112.64M
Free Float %
97.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.78% | -8.54% | -11.58% | +2.01% | -16.67% | -14.72% | +1.73% | +39.86% | +380.00% | +2,138.81% | +275.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (24 ratings, all time)
Buy
Price Targets & DCF
Current price
38.12
Low
95.00
+149.2%
Consensus
100.75
+164.3%
Median
100.50
+163.6%
High
107.00
+180.7%
DCF (Unlevered)
1.03
-97.3%
DCF (Levered)
1.47
-96.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
89% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 12 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
97.50
+155.8%
|
| Last Quarter | 4 |
98.75
+159.1%
|
| Last Year | 8 |
101.88
+167.3%
|
| All Time | 23 |
92.57
+142.8%
|
Quality scores
Altman Z-Score
15.57
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-215.8% Q1'26: -234.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +649.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.3% ★ Q1'26: +3.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 10 Rev. Ana. 13 EPS Ana. |
Dec 2028 10 Rev. Ana. 12 EPS Ana. |
Dec 2029 5 Rev. Ana. 10 EPS Ana. |
Dec 2030 5 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 6.19M (-100.0%)
|
—
|
—
est: 1.47M (-100.0%)
|
7.17M
7.17M – 7.17M
+387.4% YoY
|
7.35M
7.35M – 7.35M
+2.5% YoY
|
126.57M
126.57M – 126.57M
+1,622.3% YoY
|
403.74M
403.74M – 403.74M
+219.0% YoY
|
1.21B
1.21B – 1.21B
+200.8% YoY
|
| EBITDA |
-39.11M
est: -28.74M (-36.1%)
|
-150.58M
|
-393.34M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-39.39M
est: -43.82M (+10.1%)
|
-150.92M
|
-393.34M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-39.50M
est: -29.66M (-33.2%)
|
-109.96M
est: -113.12M (+2.8%)
|
-359.64M
est: -301.54M (-19.3%)
|
-563.59M
-661.40M – -387.36M
-86.9% YoY
|
-576.27M
-758.82M – -262.80M
-2.2% YoY
|
-547.99M
-840.84M – -221.50M
+4.9% YoY
|
-236.86M
-236.86M – -236.86M
+56.8% YoY
|
247.30M
247.30M – 247.30M
+204.4% YoY
|
| SGA |
10.73M
|
49.28M
|
48.39M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.50
est: -0.55 (+8.9%)
|
-1.01
est: -0.96 (-4.9%)
|
-3.19
est: -2.72 (-17.2%)
|
-4.68
-5.87 – -3.44
-71.9% YoY
|
-4.62
-6.74 – -2.33
+1.2% YoY
|
-4.10
-7.46 – -1.97
+11.4% YoY
|
-2.10
-2.10 – -2.10
+48.7% YoY
|
2.19
2.19 – 2.19
+204.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-30 | Cantor Fitzgerald | Overweight | Overweight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
99
Total invested
99.16M
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 10.92M | 11.42% | 10.92M | — | 10.92M | — | HC | Delaware | 2023-04-10 | ↗ |
| 2 | (1)Names of reporting persons. BlackRock, Inc. | 7.61M | 7.60% | 7.50M | — | 7.61M | — | HC | Delaware | 2024-01-26 | ↗ |
| 3 | Ligand Pharmaceuticals Incorporated | 7.34M | 9.90% | — | 7.34M | — | 7.34M | CO | — | 2020-08-28 | ↗ |
| 4 | Abigail P. Johnson | 7.22M | 10.30% | — | — | 7.22M | — | IN | Delaware | 2018-10-10 | ↗ |
| 5 | ArrowMark Colorado Holdings, LLC | 7.06M | 9.03% | 7.06M | — | 7.06M | — | IA | Delaware, United States | 2022-02-14 | ↗ |
| 6 | David C. Ott | 5.86M | 5.90% | — | 5.86M | — | 5.86M | IN | Delaware | 2023-11-02 | ↗ |
| 7 | O. Andreas Halvorsen | 5.86M | 5.90% | — | 5.86M | — | 5.86M | IN | Delaware | 2023-11-02 | ↗ |
| 8 | Rose S. Shabet | 5.86M | 5.90% | — | 5.86M | — | 5.86M | IN | Delaware | 2023-11-02 | ↗ |
| 9 | Viking Global Investors LP | 5.86M | 5.90% | — | 5.86M | — | 5.86M | PN | Delaware | 2023-11-02 | ↗ |
| 10 | The Vanguard Group - 23-1945930 | 5.38M | 5.38% | — | — | 5.13M | 256.7K | IA | — | 2024-02-13 | ↗ |
| 11 | Israel A. Englander | 4.83M | 6.30% | — | 4.83M | — | 4.83M | IN | — | 2023-01-03 | ↗ |
| 12 | Millennium Group Management LLC | 4.83M | 6.30% | — | 4.83M | — | 4.83M | OO | — | 2023-01-03 | ↗ |
| 13 | Millennium Management LLC | 4.83M | 6.30% | — | 4.83M | — | 4.83M | OO | — | 2023-01-03 | ↗ |
| 14 | Viking Global Performance LLC | 4.40M | 4.40% | — | 4.40M | — | 4.40M | OO | Delaware | 2023-11-02 | ↗ |
| 15 | Viking Global Equities Master Ltd. | 4.31M | 4.30% | — | 4.31M | — | 4.31M | CO | Delaware | 2023-11-02 | ↗ |
| 16 | STATE STREET CORPORATION | 4.13M | 5.27% | — | 3.96M | — | 4.13M | HC | BOSTON, MASSACHUSETTS | 2022-02-14 | ↗ |
| 17 | SSGA FUNDS MANAGEMENT, INC. | 3.87M | 5.30% | — | 3.85M | — | 3.87M | IA | — | 2021-02-11 | ↗ |
| 18 | Brian Lian, Ph.D. | 1.55M | 7.40% | 1.55M | — | 1.55M | — | IN | United States | 2017-02-14 | ↗ |
| 19 | Viking Long Fund GP LLC | 1.46M | 1.50% | — | 1.46M | — | 1.46M | OO | Delaware | 2023-11-02 | ↗ |
| 20 | Viking Long Fund Master Ltd. | 1.46M | 1.50% | — | 1.46M | — | 1.46M | CO | Delaware | 2023-11-02 | ↗ |
| 21 | (1) BlackRock, Inc. | 1.43M | 1.80% | 1.40M | — | 1.43M | — | HC | Delaware | 2022-07-08 | ↗ |
| 22 | Capital, LLC | 1.29M | 5.70% | 1.29M | — | 1.29M | — | OO | California | 2017-02-17 | ↗ |
| 23 | Evans | 1.29M | 5.70% | 1.29M | — | 1.29M | — | IN | States | 2017-02-17 | ↗ |
| 24 | Evans Family Trust, dated January 28, 2016 | 1.29M | 5.70% | 1.29M | — | 1.29M | — | OO | States | 2017-02-17 | ↗ |
| 25 | Moshe Arkin | 770.7K | 1.08% | 25.0K | 745.7K | 25.0K | — | IN | Israel | 2019-02-13 | ↗ |
| 26 | Sphera Funds Management Ltd. | 745.7K | 1.04% | — | 745.7K | — | — | CO | Israel | 2019-02-13 | ↗ |
| 27 | Sphera Global Healthcare GP Ltd. | 745.7K | 1.04% | — | 745.7K | — | — | CO | Israel | 2019-02-13 | ↗ |
| 28 | Sphera Global Healthcare Management LP | 745.7K | 1.04% | — | 745.7K | — | — | CO | Israel | 2019-02-13 | ↗ |
| 29 | Michael Dinerman, M.D. | 589.1K | 6.10% | 589.1K | — | 589.1K | — | IN | United States | 2016-02-16 | ↗ |
| 30 | Viking Global Equities II LP | 88.0K | 0.10% | — | 88.0K | — | 88.0K | PN | Delaware | 2023-11-02 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
99
-362 vs prev Q
New positions
10
Closed positions
340
Increased
48
Reduced
24
Put/Call ratio
0.00
Calls held
362.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 330.1K +330.1K (+100.0%) | 11.61B +11.6B (+100.0%) | 0.29% +0.293 pp | 0.02% +0.018 pp | USD35.18 +0.0% | 1 qtrs NEW |
| 2 | — | 134.5K +134.5K (+100.0%) | 5.31B +5.3B (+100.0%) | 0.12% +0.119 pp | 0.42% +0.422 pp | USD35.18 +0.0% | 1 qtrs NEW |
| 3 | VANGUARD GROUP INC | 9.98M -14.6K (-0.1%) | 351.25M +88.5M (+33.7%) | 8.86% -0.055 pp | 0.01% +0.001 pp | USD37.46 -6.1% | 43 qtrs — |
| 4 | BLACKROCK, INC. | 6.61M +1.0M (+18.2%) | 232.61M +85.5M (+58.2%) | 5.87% +0.878 pp | 0.00% +0.001 pp | USD55.98 -37.2% | 6 qtrs — |
| 5 | FMR LLC | 6.56M +767.7K (+13.3%) | 230.70M +78.5M (+51.6%) | 5.75% +0.589 pp | 0.01% +0.004 pp | USD23.88 +47.3% | 16 qtrs — |
| 6 | STATE STREET CORP | 4.45M -68.4K (-1.5%) | 156.39M +37.8M (+31.8%) | 3.95% -0.080 pp | 0.01% +0.001 pp | USD29.17 +20.6% | 32 qtrs — |
| 7 | MORGAN STANLEY | 3.08M -652.8K (-17.5%) | 108.22M +10.2M (+10.4%) | 2.73% -0.595 pp | 0.01% +0.001 pp | USD34.91 +0.8% | 32 qtrs — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.98M +1.0M (+50.8%) | 104.80M +52.9M (+101.9%) | 2.64% +0.883 pp | 0.01% +0.006 pp | USD44.39 -20.7% | 32 qtrs — |
| 9 | TWO SIGMA INVESTMENTS, LP | 2.44M +350.3K (+16.8%) | 85.69M +30.9M (+56.3%) | 2.16% +0.302 pp | 0.12% +0.039 pp | USD27.63 +27.3% | 23 qtrs — |
| 10 | TWO SIGMA ADVISERS, LP | 2.13M +574.1K (+36.9%) | 74.91M +34.0M (+83.3%) | 1.89% +0.503 pp | 0.15% +0.064 pp | USD28.79 +22.2% | 3 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1.99M +385.9K (+24.0%) | 70.18M +27.9M (+66.0%) | 1.77% +0.336 pp | 0.00% +0.002 pp | USD22.39 +57.1% | 39 qtrs — |
| 12 | CITADEL ADVISORS LLC | 1.73M -165.9K (-8.7%) | 60.95M +11.1M (+22.2%) | 1.54% -0.155 pp | 0.01% +0.002 pp | USD42.89 -18.0% | 24 qtrs — |
| 13 | D. E. SHAW & CO., INC. | 1.72M +1.6M (+965.0%) | 60.46M +56.2M (+1,325.7%) | 1.51% +1.364 pp | 0.03% +0.031 pp | USD34.88 +0.9% | 16 qtrs — |
| 14 | AMERIPRISE FINANCIAL INC | 1.34M -753.7K (-36.0%) | 47.11M -7.9M (-14.3%) | 1.17% -0.692 pp | 0.01% -0.002 pp | USD41.25 -14.7% | 9 qtrs — |
| 15 | BNP PARIBAS ARBITRAGE, SNC | 992.7K +836.4K (+535.1%) | 34.92M +30.8M (+750.2%) | 0.88% +0.742 pp | 0.02% +0.014 pp | USD33.72 +4.3% | 31 qtrs — |
| 16 | UBS GROUP AG | 934.9K -407.4K (-30.3%) | 32.89M -2.4M (-6.8%) | 0.83% -0.367 pp | 0.01% 0.000 pp | USD29.15 +20.7% | 33 qtrs — |
| 17 | RAYMOND JAMES FINANCIAL INC | 922.0K -32.3K (-3.4%) | 32.44M +7.4M (+29.3%) | 0.81% -0.042 pp | 0.01% +0.002 pp | USD35.30 -0.3% | 5 qtrs — |
| 18 | GOLDMAN SACHS GROUP INC | 832.7K +564.9K (+211.0%) | 29.29M +22.3M (+316.3%) | 0.74% +0.503 pp | 0.00% +0.003 pp | USD32.97 +6.7% | 32 qtrs — |
| 19 | PICTET ASSET MANAGEMENT HOLDING SA | 752.7K -443.6K (-37.1%) | 26.48M -5.0M (-15.8%) | 0.67% -0.397 pp | 0.03% -0.005 pp | USD39.99 -12.0% | 10 qtrs — |
| 20 | ARTIA GLOBAL PARTNERS LP | 719.4K +573.2K (+392.1%) | 25.31M +21.5M (+558.8%) | 0.64% +0.508 pp | 4.04% +3.428 pp | USD33.81 +4.1% | 13 qtrs — |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 700.3K +2.6K (+0.4%) | 24.64M +6.3M (+34.4%) | 0.61% -0.008 pp | 0.00% +0.001 pp | USD21.00 +67.5% | 31 qtrs — |
| 22 | JANE STREET GROUP, LLC | 636.0K -69.5K (-9.9%) | 22.37M +3.8M (+20.7%) | 0.57% -0.063 pp | 0.00% +0.001 pp | USD45.19 -22.2% | 6 qtrs — |
| 23 | BLACKBARN CAPITAL PARTNERS LP | 550.0K +50.0K (+10.0%) | 19.35M +6.2M (+47.3%) | 0.49% +0.042 pp | 1.27% +0.332 pp | USD27.23 +29.2% | 3 qtrs — |
| 24 | JPMORGAN CHASE & CO | 546.8K -2.0M (-78.8%) | 19.24M -48.5M (-71.6%) | 0.49% -1.811 pp | 0.00% -0.003 pp | USD42.21 -16.7% | 31 qtrs — |
| 25 | NORTHERN TRUST CORP | 541.1K -16.2K (-2.9%) | 19.03M +4.4M (+30.0%) | 0.47% -0.022 pp | 0.00% +0.001 pp | USD20.11 +74.9% | 39 qtrs — |
| 26 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 518.8K -25.4K (-4.7%) | 18.25M +3.9M (+27.6%) | 0.46% -0.025 pp | 0.05% +0.003 pp | USD37.31 -5.7% | 7 qtrs — |
| 27 | BARCLAYS PLC | 516.7K +413.5K (+401.0%) | 18.18M +11.6M (+178.4%) | 0.46% +0.367 pp | 0.00% +0.003 pp | USD32.79 +7.3% | 33 qtrs — |
| 28 | PRINCIPAL FINANCIAL GROUP INC | 513.7K -271.0 (-0.1%) | 18.07M +4.6M (+33.8%) | 0.46% -0.001 pp | 0.01% +0.002 pp | USD68.97 -49.0% | 11 qtrs — |
| 29 | TANG CAPITAL MANAGEMENT LLC | 500.0K -370.0K (-42.5%) | 17.59M -5.3M (-23.1%) | 0.44% -0.332 pp | 0.87% -0.011 pp | USD34.74 +1.3% | 8 qtrs — |
| 30 | BANK OF NEW YORK MELLON CORP | 474.6K -25.2K (-5.0%) | 16.70M +3.6M (+27.1%) | 0.42% -0.024 pp | 0.00% +0.000 pp | USD24.25 +45.1% | 32 qtrs — |
| 31 | DIMENSIONAL FUND ADVISORS LP | 459.6K -11.7K (-2.5%) | 16.17M +3.8M (+30.5%) | 0.40% -0.017 pp | 0.00% +0.001 pp | USD26.39 +33.3% | 29 qtrs — |
| 32 | ROYAL BANK OF CANADA | 455.4K -192.9K (-29.8%) | 16.02M -1.0M (-6.0%) | 0.40% -0.174 pp | 0.00% 0.000 pp | USD39.72 -11.4% | 33 qtrs — |
| 33 | CLEARBRIDGE INVESTMENTS, LLC | 444.8K +630.0 (+0.1%) | 15.65M +4.0M (+34.1%) | 0.39% -0.001 pp | 0.01% +0.004 pp | USD76.07 -53.8% | 8 qtrs — |
| 34 | BLAIR WILLIAM & CO/IL | 424.0K +68.0K (+19.1%) | 14.92M +5.6M (+59.5%) | 0.38% +0.059 pp | 0.04% +0.015 pp | USD49.64 -29.1% | 31 qtrs — |
| 35 | WALLEYE TRADING LLC | 389.8K -8.8K (-2.2%) | 13.71M +3.2M (+30.9%) | 0.34% -0.014 pp | 0.02% +0.004 pp | USD27.21 +29.3% | 13 qtrs — |
| 36 | FIRST WASHINGTON CORP | 387.5K +120.7K (+45.2%) | 13.63M +6.6M (+94.4%) | 0.34% +0.106 pp | 3.53% +1.651 pp | USD32.72 +7.5% | 9 qtrs — |
| 37 | BANK OF AMERICA CORP /DE/ | 346.6K -231.6K (-40.1%) | 12.20M -3.0M (-19.8%) | 0.31% -0.208 pp | 0.00% 0.000 pp | USD19.77 +77.9% | 32 qtrs — |
| 38 | DIADEMA PARTNERS LP | 336.8K +143.2K (+73.9%) | 11.85M +6.8M (+132.8%) | 0.30% +0.126 pp | 2.04% +0.739 pp | USD29.48 +19.3% | 4 qtrs — |
| 39 | STIFEL FINANCIAL CORP | 336.8K -13.5K (-3.9%) | 11.85M +2.6M (+28.7%) | 0.30% -0.017 pp | 0.01% +0.002 pp | USD38.41 -8.4% | 9 qtrs — |
| 40 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 326.4K +306.4K (+1,532.0%) | 11.47M +10.9M (+2,089.5%) | 0.29% +0.272 pp | 0.09% +0.085 pp | USD36.01 -2.3% | 8 qtrs — |
| 41 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 316.3K +8.0K (+2.6%) | 11.13M +3.0M (+37.3%) | 0.28% +0.006 pp | 0.06% +0.015 pp | USD43.09 -18.4% | 14 qtrs — |
| 42 | POINT72 ASSET MANAGEMENT, L.P. | 313.5K +313.5K (+100.0%) | 11.03M +11.0M (+100.0%) | 0.28% +0.275 pp | 0.01% +0.012 pp | USD35.18 +0.0% | 3 qtrs — |
| 43 | AMERICAN CENTURY COMPANIES INC | 305.4K +9.2K (+3.1%) | 10.74M +3.0M (+38.0%) | 0.27% +0.007 pp | 0.01% +0.001 pp | USD17.46 +101.5% | 13 qtrs — |
| 44 | WOODLINE PARTNERS LP | 302.0K +38.0 (+0.0%) | 10.63M +2.7M (+33.9%) | 0.27% -0.001 pp | 0.04% +0.004 pp | USD37.41 -6.0% | 8 qtrs — |
| 45 | WELLS FARGO & COMPANY/MN | 281.3K -31.3K (-10.0%) | 9.89M +1.7M (+20.5%) | 0.25% -0.029 pp | 0.00% +0.000 pp | USD34.37 +2.4% | 31 qtrs — |
| 46 | CONCURRENT INVESTMENT ADVISORS, LLC | 281.1K +264.8K (+1,624.0%) | 9.89M +9.5M (+2,207.9%) | 0.25% +0.236 pp | 0.11% +0.105 pp | USD34.60 +1.7% | 4 qtrs — |
| 47 | MAN GROUP PLC | 260.3K +250.8K (+2,628.8%) | 9.16M +8.9M (+3,552.9%) | 0.23% +0.220 pp | 0.02% +0.015 pp | USD35.38 -0.6% | 7 qtrs — |
| 48 | GOTHAM ASSET MANAGEMENT, LLC | 239.2K +69.5K (+41.0%) | 8.42M +4.0M (+88.7%) | 0.21% +0.061 pp | 0.03% +0.011 pp | USD28.87 +21.9% | 4 qtrs — |
| 49 | UBS ASSET MANAGEMENT AMERICAS INC | 238.2K -5.5K (-2.3%) | 8.38M +2.0M (+30.8%) | 0.21% -0.008 pp | 0.00% +0.000 pp | USD22.83 +54.1% | 10 qtrs — |
| 50 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 235.6K +46.1K (+24.3%) | 8.29M +3.3M (+66.4%) | 0.21% +0.040 pp | 0.35% +0.151 pp | USD60.74 -42.1% | 8 qtrs — |
| 51 | CAPTION MANAGEMENT, LLC | 221.0K -690.9K (-75.8%) | 7.77M -16.2M (-67.6%) | 0.20% -0.617 pp | 0.05% -0.134 pp | USD26.54 +32.6% | 12 qtrs — |
| 52 | SCHRODER INVESTMENT MANAGEMENT GROUP | 214.5K +68.0K (+46.4%) | 7.58M +3.8M (+100.3%) | 0.19% +0.060 pp | 0.01% +0.003 pp | USD32.40 +8.6% | 7 qtrs — |
| 53 | SWISS NATIONAL BANK | 210.7K +3.9K (+1.9%) | 7.41M +2.0M (+36.4%) | 0.19% +0.003 pp | 0.00% +0.001 pp | USD22.66 +55.3% | 12 qtrs — |
| 54 | NUVEEN, LLC | 210.4K +15.2K (+7.8%) | 7.40M +2.3M (+44.3%) | 0.19% +0.013 pp | 0.00% +0.001 pp | USD24.98 +40.8% | 4 qtrs — |
| 55 | ACT CAPITAL MANAGEMENT, LLC | 206.1K +206.1K (+100.0%) | 7.25M +7.3M (+100.0%) | 0.18% +0.183 pp | 5.86% +5.863 pp | USD35.18 +0.0% | 1 qtrs NEW |
| 56 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 192.4K +150.2K (+356.4%) | 6.77M +5.7M (+510.9%) | 0.17% +0.133 pp | 0.02% +0.020 pp | USD33.23 +5.9% | 4 qtrs — |
| 57 | CETERA INVESTMENT ADVISERS | 189.6K +1.2K (+0.6%) | 6.67M +1.7M (+34.7%) | 0.17% +0.000 pp | 0.01% +0.002 pp | USD42.70 -17.6% | 8 qtrs — |
| 58 | PFM HEALTH SCIENCES, LP | 189.0K +5.4K (+3.0%) | 6.65M +1.8M (+37.8%) | 0.17% +0.004 pp | 0.66% +0.292 pp | USD26.58 +32.4% | 3 qtrs — |
| 59 | LPL FINANCIAL LLC | 179.9K -16.7K (-8.5%) | 6.33M +1.2M (+22.5%) | 0.16% -0.016 pp | 0.00% +0.000 pp | USD29.31 +20.0% | 28 qtrs — |
| 60 | WASATCH ADVISORS LP | 165.4K +36.9K (+28.8%) | 5.82M +2.4M (+72.4%) | 0.15% +0.031 pp | 0.03% +0.016 pp | USD22.88 +53.8% | 12 qtrs — |
| 61 | OPPENHEIMER & CO INC | 156.7K -27.7K (-15.0%) | 5.51M +667.3K (+13.8%) | 0.14% -0.025 pp | 0.08% +0.019 pp | USD40.80 -13.8% | 11 qtrs — |
| 62 | RAFFERTY ASSET MANAGEMENT, LLC | 155.0K -44.4K (-22.3%) | 5.45M +213.3K (+4.1%) | 0.14% -0.040 pp | 0.02% +0.002 pp | USD36.96 -4.8% | 12 qtrs — |
| 63 | HUDSON BAY CAPITAL MANAGEMENT LP | 150.0K +150.0K (+100.0%) | 5.28M +5.3M (+100.0%) | 0.13% +0.133 pp | 0.02% +0.017 pp | USD35.18 +0.0% | 1 qtrs NEW |
| 64 | MILLENNIUM MANAGEMENT LLC | 150.0K -54.6K (-26.7%) | 5.28M -99.9K (-1.9%) | 0.13% -0.049 pp | 0.00% 0.000 pp | USD34.68 +1.4% | 13 qtrs — |
| 65 | GROUP ONE TRADING, L.P. | 143.6K +107.8K (+301.0%) | 5.05M +4.1M (+436.8%) | 0.13% +0.096 pp | 0.01% +0.007 pp | USD39.41 -10.7% | 32 qtrs — |
| 66 | RFG ADVISORY, LLC | 143.6K +23.3K (+19.4%) | 5.05M +1.9M (+59.9%) | 0.13% +0.021 pp | 0.10% +0.030 pp | USD27.18 +29.4% | 4 qtrs — |
| 67 | 683 CAPITAL MANAGEMENT, LLC | 136.5K +36.5K (+36.5%) | 4.80M +2.2M (+82.7%) | 0.12% +0.032 pp | 0.21% +0.072 pp | USD28.66 +22.7% | 2 qtrs — |
| 68 | PEAK6 LLC | 126.1K +126.1K (+100.0%) | 4.44M +4.4M (+100.0%) | 0.11% +0.112 pp | 0.01% +0.008 pp | USD35.18 +0.0% | 1 qtrs NEW |
| 69 | BAMCO INC /NY/ | 125.8K -910.0 (-0.7%) | 4.43M +1.1M (+32.9%) | 0.11% -0.003 pp | 0.01% +0.003 pp | USD40.77 -13.7% | 9 qtrs — |
| 70 | RHUMBLINE ADVISERS | 119.7K +5.9K (+5.2%) | 4.21M +1.2M (+40.8%) | 0.11% +0.005 pp | 0.00% +0.001 pp | USD24.21 +45.3% | 11 qtrs — |
| 71 | VERITION FUND MANAGEMENT LLC | 112.7K +99.0K (+720.6%) | 3.97M +3.6M (+998.5%) | 0.10% +0.087 pp | 0.02% +0.014 pp | USD34.10 +3.2% | 8 qtrs — |
| 72 | LEGAL & GENERAL GROUP PLC | 108.5K -3.1K (-2.8%) | 3.82M +883.9K (+30.1%) | 0.10% -0.003 pp | 0.00% +0.000 pp | USD22.03 +59.7% | 12 qtrs — |
| 73 | INSTITUTE FOR WEALTH MANAGEMENT, LLC. | 107.9K +4.5K (+4.3%) | 3.80M +1.1M (+39.6%) | 0.10% +0.004 pp | 0.40% +0.119 pp | USD38.50 -8.6% | 25 qtrs — |
| 74 | INVESCO LTD. | 107.2K -2.1K (-1.9%) | 3.77M +897.8K (+31.3%) | 0.10% -0.002 pp | 0.00% +0.000 pp | USD57.25 -38.6% | 13 qtrs — |
| 75 | QUANTUM PRIVATE WEALTH, LLC | 105.3K +319.0 (+0.3%) | 3.71M +945.9K (+34.3%) | 0.09% 0.000 pp | 1.08% +0.276 pp | USD19.63 +79.2% | 17 qtrs — |
| 76 | BRIDGEWATER ASSOCIATES, LP | 103.7K -19.8K (-16.1%) | 3.65M +401.4K (+12.4%) | 0.09% -0.018 pp | 0.01% +0.001 pp | USD26.28 +33.9% | 2 qtrs — |
| 77 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 102.4K +1.4K (+1.4%) | 3.60M +949.1K (+35.8%) | 0.09% 0.000 pp | 0.00% +0.001 pp | USD21.11 +66.7% | 12 qtrs — |
| 78 | WALLEYE CAPITAL LLC | 100.8K +10.1K (+11.1%) | 3.55M +1.2M (+48.8%) | 0.09% +0.008 pp | 0.01% +0.002 pp | USD36.02 -2.3% | 12 qtrs — |
| 79 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 100.0K +100.0K (+100.0%) | 3.52M +3.5M (+100.0%) | 0.09% +0.088 pp | 0.17% +0.175 pp | USD35.18 +0.0% | 1 qtrs NEW |
| 80 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 95.0K +770.0 (+0.8%) | 3.34M +866.0K (+35.0%) | 0.08% -0.001 pp | 0.01% +0.002 pp | USD48.94 -28.1% | 11 qtrs — |
| 81 | AQUATIC CAPITAL MANAGEMENT LLC | 94.3K +94.3K (+100.0%) | 3.32M +3.3M (+100.0%) | 0.08% +0.084 pp | 0.09% +0.094 pp | USD35.18 +0.0% | 5 qtrs — |
| 82 | ALPS ADVISORS INC | 92.6K +37.8K (+68.9%) | 3.26M +1.8M (+126.1%) | 0.08% +0.033 pp | 0.02% +0.011 pp | USD30.04 +17.1% | 3 qtrs — |
| 83 | PRICE T ROWE ASSOCIATES INC /MD/ | 91.2K +5.7K (+6.7%) | 3.21M +962.0K (+42.8%) | 0.08% +0.005 pp | 0.00% +0.000 pp | USD25.82 +36.3% | 11 qtrs — |
| 84 | PERSISTENT ASSET PARTNERS LTD | 90.5K +45.9K (+103.0%) | 3.18M +2.0M (+171.8%) | 0.08% +0.041 pp | 1.43% +0.625 pp | USD30.30 +16.1% | 4 qtrs — |
| 85 | SOROS FUND MANAGEMENT LLC | 90.0K +90.0K (+100.0%) | 3.17M +3.2M (+100.0%) | 0.08% +0.079 pp | 0.04% +0.037 pp | USD35.18 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.57
Bullish
Ratio by volume
2.96
Bullish
Buys
22
Sells
14
Shares acquired
1.13M
Shares disposed
380.7K
Cash buys
1.00
Cash sales
13.00
Net activity
+744,372
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | Aubuchon Neil William | Officer | P-Purchase | A | Common Stock, par value $0.00001 per share | 4,475 | 33.50 | 149.9K | 4,475 | D | ↗ |
| 2026-01-12 | Aubuchon Neil William | Officer | A-Award | A | Stock Option (Right to Buy) | 180,000 | 31.76 | 5.72M | 180,000 | D | ↗ |
| 2026-01-05 | ZANTE GREG | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 1,500 | 32.09 | 48.1K | 189,891 | D | ↗ |
| 2026-01-05 | Mancini Marianna | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 1,600 | 35.07 | 56.1K | 409,190 | D | ↗ |
| 2026-01-05 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 41,276 | 34.22 | 1.41M | 2,505,691 | D | ↗ |
| 2026-01-02 | ZANTE GREG | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 32,049 | 0.00 | — | 247,532 | D | ↗ |
| 2026-01-02 | SINGLETON J MATTHEW | Director | A-Award | A | Common Stock, par value $0.00001 per share | 3,150 | 0.00 | — | 12,650 | D | ↗ |
| 2026-01-02 | Rowland Charles A Jr | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 35.42 | 722.6K | 20,400 | D | ↗ |
| 2026-01-02 | Rouan Sarah Kathryn | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 35.42 | 722.6K | 20,400 | D | ↗ |
| 2026-01-02 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 32,049 | 0.00 | — | 466,851 | D | ↗ |
| 2026-01-02 | MACARTNEY LAWSON | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 35.42 | 722.6K | 20,400 | D | ↗ |
| 2026-01-02 | Lian Brian | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 176,300 | 35.42 | 6.24M | 176,300 | D | ↗ |
| 2026-01-02 | FOEHR MATTHEW W | Director | A-Award | A | Common Stock, par value $0.00001 per share | 3,150 | 0.00 | — | 135,186 | D | ↗ |
| 2025-10-28 | ZANTE GREG | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 6,185 | 35.00 | 216.5K | 173,592 | D | ↗ |
| 2025-10-28 | Mancini Marianna | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 6,185 | 35.00 | 216.5K | 382,467 | D | ↗ |
| 2025-10-28 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 38,989 | 35.01 | 1.36M | 2,419,109 | D | ↗ |
| 2025-10-27 | ZANTE GREG | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 11,117 | 0.00 | — | 179,777 | D | ↗ |
| 2025-10-27 | Rowland Charles A Jr | Director | M-Exempt | D | Stock Option (Right to Buy) | 16,000 | 4.48 | 71.7K | 0 | D | ↗ |
| 2025-10-27 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 11,117 | 0.00 | — | 388,652 | D | ↗ |
| 2025-10-27 | Lian Brian | Director / Officer | A-Award | A | Common Stock, par value $0.00001 per share | 70,084 | 0.00 | — | 2,458,098 | D | ↗ |
| 2025-07-03 | ZANTE GREG | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 4,266 | 27.76 | 118.4K | 168,660 | D | ↗ |
| 2025-07-03 | Mancini Marianna | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 4,266 | 27.77 | 118.5K | 377,535 | D | ↗ |
| 2025-07-03 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 26,889 | 27.80 | 747.6K | 2,388,014 | D | ↗ |
| 2025-07-02 | ZANTE GREG | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 7,667 | 0.00 | — | 172,926 | D | ↗ |
| 2025-07-02 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 7,667 | 0.00 | — | 381,801 | D | ↗ |
| 2025-07-02 | Lian Brian | Director / Officer | A-Award | A | Common Stock, par value $0.00001 per share | 48,333 | 0.00 | — | 2,414,903 | D | ↗ |
| 2025-04-11 | FOEHR MATTHEW W | Director | M-Exempt | A | Common Stock, par value $0.00001 per share | 20,786 | 8.00 | 166.3K | 132,036 | D | ↗ |
| 2025-03-31 | Rouan Sarah Kathryn | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 1,240 | 24.15 | 29.9K | 1,240 | D | ↗ |
| 2025-01-06 | ZANTE GREG | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 4,700 | 43.32 | 203.6K | 165,259 | D | ↗ |
| 2025-01-06 | Mancini Marianna | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 5,100 | 43.32 | 220.9K | 374,134 | D | ↗ |
| 2025-01-06 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 175,490 | 42.68 | 7.49M | 2,385,570 | D | ↗ |
| 2025-01-03 | ZANTE GREG | Officer | A-Award | A | Stock Option (Right to Buy) | 37,200 | 42.89 | 1.60M | 37,200 | D | ↗ |
| 2025-01-03 | Mancini Marianna | Officer | A-Award | A | Stock Option (Right to Buy) | 37,200 | 42.89 | 1.60M | 37,200 | D | ↗ |
| 2025-01-03 | Lian Brian | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 78,300 | 42.89 | 3.36M | 78,300 | D | ↗ |
| 2025-01-02 | SINGLETON J MATTHEW | Director | A-Award | A | Stock Option (Right to Buy) | 18,800 | 41.12 | 773.1K | 18,800 | D | ↗ |
| 2025-01-02 | Rowland Charles A Jr | Director | A-Award | A | Stock Option (Right to Buy) | 18,800 | 41.12 | 773.1K | 18,800 | D | ↗ |
| 2025-01-02 | Rouan Sarah Kathryn | Director | A-Award | A | Stock Option (Right to Buy) | 18,800 | 41.12 | 773.1K | 18,800 | D | ↗ |
| 2025-01-02 | MACARTNEY LAWSON | Director | A-Award | A | Stock Option (Right to Buy) | 18,800 | 41.12 | 773.1K | 18,800 | D | ↗ |
| 2025-01-02 | FOEHR MATTHEW W | Director | A-Award | A | Stock Option (Right to Buy) | 18,800 | 41.12 | 773.1K | 18,800 | D | ↗ |
| 2024-11-08 | MACARTNEY LAWSON | Director | M-Exempt | A | Common Stock, par value $0.00001 per share | 2,000 | 5.80 | 11.6K | 49,965 | D | ↗ |
| 2024-10-28 | ZANTE GREG | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 6,050 | 79.78 | 482.7K | 158,539 | D | ↗ |
| 2024-10-25 | SINGLETON J MATTHEW | Director | M-Exempt | D | Stock Option (Right to Buy) | 16,000 | 4.48 | 71.7K | 0 | D | ↗ |
| 2024-10-25 | Rouan Sarah Kathryn | Director | S-Sale | D | Common Stock, par value $0.00001 per share | 11,000 | 80.89 | 889.8K | 0 | D | ↗ |
| 2024-09-20 | SINGLETON J MATTHEW | Director | M-Exempt | A | Common Stock, par value $0.00001 per share | 10,300 | 1.19 | 12.3K | 19,800 | D | ↗ |
| 2024-09-20 | Lian Brian | Director / Officer | M-Exempt | A | Common Stock, par value $0.00001 per share | 166,130 | 7.77 | 1.29M | 2,521,057 | D | ↗ |
| 2024-08-21 | SINGLETON J MATTHEW | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,700 | 1.19 | 6.8K | 10,300 | — | ↗ |
| 2024-08-21 | Lian Brian | Director / Officer | M-Exempt | A | Common Stock, par value $0.00001 per share | 1,000 | 7.77 | 7.8K | 2,355,927 | — | ↗ |
| 2024-08-19 | SINGLETON J MATTHEW | Director | M-Exempt | D | Stock Option (Right to Buy) | 16,000 | 3.33 | 53.3K | 0 | — | ↗ |
| 2024-08-19 | Lian Brian | Director / Officer | M-Exempt | A | Common Stock, par value $0.00001 per share | 112,870 | 7.77 | 877.0K | 2,467,797 | — | ↗ |
| 2024-08-14 | SINGLETON J MATTHEW | Director | S-Sale | D | Common Stock, par value $0.00001 per share | 20,626 | 57.52 | 1.19M | 9,660 | — | ↗ |
| 2024-07-30 | ZANTE GREG | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 500 | 58.71 | 29.4K | 187,052 | — | ↗ |
| 2024-07-30 | Mancini Marianna | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 14,704 | 56.98 | 837.8K | 365,471 | — | ↗ |
| 2024-07-30 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 19,501 | 57.81 | 1.13M | 2,385,344 | — | ↗ |
| 2024-07-29 | ZANTE GREG | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 6,667 | 0.00 | — | 181,521 | — | ↗ |
| 2024-07-29 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 21,667 | 0.00 | — | 380,175 | — | ↗ |
| 2024-07-29 | Lian Brian | Director / Officer | A-Award | A | Common Stock, par value $0.00001 per share | 163,333 | 0.00 | — | 2,470,786 | — | ↗ |
| 2024-05-03 | ZANTE GREG | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 17,238 | 75.49 | 1.30M | 175,701 | — | ↗ |
| 2024-05-01 | Mancini Marianna | Officer | M-Exempt | A | Common Stock, par value $0.00001 per share | 17,999 | 4.68 | 84.2K | 366,507 | — | ↗ |
| 2024-03-27 | ZANTE GREG | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 31,667 | 0.00 | — | 223,971 | — | ↗ |
| 2024-03-27 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 31,667 | 0.00 | — | 380,175 | — | ↗ |
| 2024-03-27 | Lian Brian | Director / Officer | A-Award | A | Common Stock, par value $0.00001 per share | 221,667 | 0.00 | — | 2,420,401 | — | ↗ |
| 2024-03-01 | ZANTE GREG | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 20,093 | 85.22 | 1.71M | 192,304 | — | ↗ |
| 2024-03-01 | Mancini Marianna | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 16,958 | 85.22 | 1.45M | 348,508 | — | ↗ |
| 2024-03-01 | Lian Brian | Director / Officer | A-Award | A | Common Stock, par value $0.00001 per share | 221,667 | 0.00 | — | 2,361,549 | — | ↗ |
| 2024-02-09 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 45,000 | 29.90 | 1.35M | 2,139,882 | — | ↗ |
| 2024-02-08 | Rouan Sarah Kathryn | Director | M-Exempt | A | Common Stock, par value $0.00001 per share | 25,000 | 8.32 | 208.0K | 25,000 | — | ↗ |
| 2024-02-08 | Lian Brian | Director / Officer | M-Exempt | A | Common Stock, par value $0.00001 per share | 140,000 | 4.65 | 651.0K | 2,404,882 | — | ↗ |
| 2024-01-31 | Lian Brian | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 85,000 | 1.23 | 104.6K | 14,148 | — | ↗ |
| 2024-01-30 | Lian Brian | Director / Officer | M-Exempt | A | Common Stock, par value $0.00001 per share | 35,000 | 1.23 | 43.1K | 2,299,882 | — | ↗ |
| 2024-01-19 | Rouan Sarah Kathryn | Director | M-Exempt | A | Common Stock, par value $0.00001 per share | 30,000 | 8.32 | 249.6K | 30,000 | — | ↗ |
| 2024-01-04 | ZANTE GREG | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 13,872 | 18.58 | 257.7K | 195,730 | — | ↗ |
| 2024-01-04 | Mancini Marianna | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 14,199 | 18.58 | 263.8K | 333,799 | — | ↗ |
| 2024-01-04 | Lian Brian | Director / Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 39,552 | 18.58 | 734.9K | 2,264,882 | — | ↗ |
| 2024-01-03 | ZANTE GREG | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 28,334 | 0.00 | — | 188,724 | — | ↗ |
| 2024-01-03 | Mancini Marianna | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 16,533 | 17.40 | 287.7K | 310,675 | — | ↗ |
| 2024-01-03 | Lian Brian | Director / Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 108,525 | 17.40 | 1.89M | 2,250,549 | — | ↗ |
| 2024-01-02 | SINGLETON J MATTHEW | Director | A-Award | A | Stock Option (Right to Buy) | 32,000 | 18.28 | 585.0K | 32,000 | — | ↗ |
| 2024-01-02 | Rowland Charles A Jr | Director | A-Award | A | Stock Option (Right to Buy) | 32,000 | 18.28 | 585.0K | 32,000 | — | ↗ |
| 2024-01-02 | Rouan Sarah Kathryn | Director | A-Award | A | Stock Option (Right to Buy) | 32,000 | 18.28 | 585.0K | 32,000 | — | ↗ |
| 2024-01-02 | MACARTNEY LAWSON | Director | A-Award | A | Stock Option (Right to Buy) | 32,000 | 18.28 | 585.0K | 32,000 | — | ↗ |
| 2024-01-02 | FOEHR MATTHEW W | Director | A-Award | A | Stock Option (Right to Buy) | 32,000 | 18.28 | 585.0K | 32,000 | — | ↗ |
| 2023-05-16 | Rowland Charles A Jr | Director | S-Sale | D | Common Stock, par value $0.00001 per share | 40,000 | 25.00 | 1.00M | 30,000 | — | ↗ |
| 2023-05-16 | MACARTNEY LAWSON | Director | M-Exempt | A | Common Stock, par value $0.00001 per share | 16,000 | 1.19 | 19.0K | 63,965 | — | ↗ |
| 2023-05-01 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 45,000 | 22.45 | 1.01M | 2,197,963 | — | ↗ |
| 2023-04-24 | MACARTNEY LAWSON | Director | M-Exempt | A | Common Stock, par value $0.00001 per share | 16,000 | 3.33 | 53.3K | 63,965 | — | ↗ |
| 2023-04-19 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 35,000 | 21.45 | 750.8K | 2,242,963 | — | ↗ |
| 2023-04-17 | ZANTE GREG | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 7,500 | 20.00 | 150.0K | 149,279 | — | ↗ |
| 2023-04-17 | Mancini Marianna | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 12,500 | 20.00 | 250.0K | 287,763 | — | ↗ |
| 2023-04-17 | MACARTNEY LAWSON | Director | M-Exempt | D | Stock Option (Right to Buy) | 20,786 | 8.00 | 166.3K | 0 | — | ↗ |
| 2023-04-17 | Lian Brian | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 125,000 | 2.15 | 268.8K | 0 | — | ↗ |
| 2023-04-13 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 79,336 | 18.45 | 1.46M | 2,307,963 | — | ↗ |
| 2023-04-12 | ZANTE GREG | Officer | M-Exempt | D | Stock Option (right to buy) | 4,097 | 7.77 | 31.8K | 12,750 | — | ↗ |
| 2023-04-11 | ZANTE GREG | Officer | M-Exempt | D | Stock Option (right to buy | 8,500 | 4.68 | 39.8K | 8,500 | — | ↗ |
| 2023-04-03 | ZANTE GREG | Officer | M-Exempt | D | Stock Option (right to buy) | 30,911 | 7.77 | 240.2K | 0 | — | ↗ |
| 2023-04-03 | Lian Brian | Director / Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 22,000 | 17.85 | 392.7K | 2,232,963 | — | ↗ |
| 2023-03-31 | Lian Brian | Director / Officer | M-Exempt | A | Common Stock, par value $0.00001 per share | 67,970 | 9.49 | 645.0K | 2,322,933 | — | ↗ |
| 2023-03-30 | ZANTE GREG | Officer | M-Exempt | D | Stock Option (right to buy) | 12,250 | 4.65 | 57.0K | 0 | — | ↗ |
| 2023-03-30 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 56,667 | 0.00 | — | 318,562 | — | ↗ |
| 2023-03-30 | Lian Brian | Director / Officer | M-Exempt | A | Common Stock, par value $0.00001 per share | 19,530 | 9.49 | 185.3K | 2,408,345 | — | ↗ |
| 2023-03-29 | Mancini Marianna | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 41,242 | 16.00 | 659.9K | 261,895 | — | ↗ |
| 2023-03-28 | Mancini Marianna | Officer | M-Exempt | A | Common Stock, par value $0.00001 per share | 10,000 | 1.04 | 10.4K | 430,200 | — | ↗ |
| 2023-01-15 | Mancini Marianna | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 1,079 | 8.95 | 9.7K | 317,273 | — | ↗ |
| 2023-01-04 | ZANTE GREG | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 20,708 | 8.42 | 174.4K | 185,057 | — | ↗ |
| 2023-01-04 | Mancini Marianna | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 13,994 | 8.42 | 117.8K | 318,352 | — | ↗ |
| 2023-01-04 | Lian Brian | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 28,619 | 8.42 | 241.0K | 2,272,963 | — | ↗ |
| 2023-01-03 | ZANTE GREG | Officer | A-Award | A | Stock Option (Right to Buy) | 204,000 | 0.00 | — | 204,000 | — | ↗ |
| 2023-01-03 | SINGLETON J MATTHEW | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2023-01-03 | Rowland Charles A Jr | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2023-01-03 | Rouan Sarah Kathryn | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2023-01-03 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 90,667 | 0.00 | — | 351,200 | — | ↗ |
| 2023-01-03 | MACARTNEY LAWSON | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2023-01-03 | Lian Brian | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 266,667 | 0.00 | — | 2,369,834 | — | ↗ |
| 2023-01-03 | FOEHR MATTHEW W | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-12-30 | ZANTE GREG | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 20,233 | 0.00 | — | 158,728 | — | ↗ |
| 2022-12-30 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 23,500 | 0.00 | — | 273,306 | — | ↗ |
| 2022-12-30 | Lian Brian | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 66,127 | 9.40 | 621.6K | 2,103,167 | — | ↗ |
| 2022-05-02 | FOEHR MATTHEW W | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 45,000 | 2.47 | 111.2K | 111,250 | — | ↗ |
| 2022-01-15 | Mancini Marianna | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 827 | 4.24 | 3.5K | 238,695 | — | ↗ |
| 2022-01-04 | ZANTE GREG | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 8,835 | 4.62 | 40.8K | 136,304 | — | ↗ |
| 2022-01-04 | Mancini Marianna | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 11,845 | 4.62 | 54.7K | 239,522 | — | ↗ |
| 2022-01-04 | Lian Brian | Director / Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 26,432 | 4.62 | 122.1K | 2,036,686 | — | ↗ |
| 2022-01-03 | ZANTE GREG | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 3,097 | 4.88 | 15.1K | 91,806 | — | ↗ |
| 2022-01-03 | SINGLETON J MATTHEW | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 4.88 | 107.4K | 22,000 | — | ↗ |
| 2022-01-03 | Rowland Charles A Jr | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 4.88 | 107.4K | 22,000 | — | ↗ |
| 2022-01-03 | Rouan Sarah Kathryn | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 4.88 | 107.4K | 22,000 | — | ↗ |
| 2022-01-03 | Mancini Marianna | Officer | A-Award | A | Stock Option (Right to Buy) | 174,000 | 4.88 | 849.1K | 174,000 | — | ↗ |
| 2022-01-03 | MACARTNEY LAWSON | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 4.88 | 107.4K | 22,000 | — | ↗ |
| 2022-01-03 | Lian Brian | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 390,000 | 4.88 | 1.90M | 390,000 | — | ↗ |
| 2022-01-03 | FOEHR MATTHEW W | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 4.88 | 107.4K | 22,000 | — | ↗ |
| 2021-09-28 | ZANTE GREG | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 6,667 | 0.00 | — | 96,791 | — | ↗ |
| 2021-09-28 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 6,667 | 0.00 | — | 180,374 | — | ↗ |
| 2021-09-28 | Lian Brian | Director / Officer | A-Award | A | Common Stock, par value $0.00001 per share | 55,500 | 0.00 | — | 1,952,557 | — | ↗ |
| 2021-06-10 | FOEHR MATTHEW W | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 20,000 | 5.69 | 113.8K | 66,250 | — | ↗ |
| 2021-03-31 | ZANTE GREG | Officer | — | D | Stock Option (Right to Buy) | 17,000 | 4.68 | 79.6K | 0 | — | ↗ |
| 2021-03-31 | Mancini Marianna | Officer | — | D | Stock Option (Right to Buy) | 18,000 | 4.68 | 84.2K | 0 | — | ↗ |
| 2021-03-22 | FOEHR MATTHEW W | Director | X-InTheMoney | D | Warrants (Right to Buy) | 20,000 | 1.50 | 30.0K | 0 | — | ↗ |
| 2021-01-19 | ZANTE GREG | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 808 | 6.68 | 5.4K | 89,751 | — | ↗ |
| 2021-01-19 | Mancini Marianna | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 994 | 6.68 | 6.6K | 169,952 | — | ↗ |
| 2021-01-19 | MORNEAU MICHAEL | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 1,685 | 6.68 | 11.3K | 116,062 | — | ↗ |
| 2021-01-19 | Lian Brian | Director / Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 5,611 | 6.68 | 37.5K | 1,894,181 | — | ↗ |
| 2021-01-15 | Mancini Marianna | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 686 | 6.48 | 4.4K | 170,946 | — | ↗ |
| 2021-01-04 | ZANTE GREG | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 2,787 | 5.80 | 16.2K | 90,559 | — | ↗ |
| 2021-01-04 | SINGLETON J MATTHEW | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 5.80 | 127.6K | 22,000 | — | ↗ |
| 2021-01-04 | Rowland Charles A Jr | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 5.80 | 127.6K | 22,000 | — | ↗ |
| 2021-01-04 | Rouan Sarah Kathryn | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 5.80 | 127.6K | 22,000 | — | ↗ |
| 2021-01-04 | Mancini Marianna | Officer | A-Award | A | Common Stock, par value $0.00001 per share | 73,000 | 0.00 | — | 167,655 | — | ↗ |
| 2021-01-04 | MORNEAU MICHAEL | Officer | A-Award | A | Stock Option (Right to Buy) | 33,000 | 5.80 | 191.4K | 33,000 | — | ↗ |
| 2021-01-04 | MACARTNEY LAWSON | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 5.80 | 127.6K | 22,000 | — | ↗ |
| 2021-01-04 | Lian Brian | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 369,000 | 5.80 | 2.14M | 369,000 | — | ↗ |
| 2021-01-04 | FOEHR MATTHEW W | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 5.80 | 127.6K | 22,000 | — | ↗ |
| 2021-01-03 | ZANTE GREG | Officer | — | D | Stock Option (Right to Buy) | 51,000 | 7.77 | 396.3K | 0 | — | ↗ |
| 2021-01-03 | Mancini Marianna | Officer | — | D | Stock Option (Right to Buy) | 54,000 | 7.77 | 419.6K | 0 | — | ↗ |
| 2021-01-03 | Lian Brian | Director / Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 31,545 | 5.63 | 177.6K | 1,712,432 | — | ↗ |
| 2020-10-31 | Mancini Marianna | Officer | — | D | Stock Option (Right to Buy) | 4,000 | 6.47 | 25.9K | 0 | — | ↗ |
| 2020-09-15 | MORNEAU MICHAEL | Officer | F-InKind | D | Common Stock | 1,557 | 6.25 | 9.7K | 97,873 | — | ↗ |
| 2020-09-15 | Lian Brian | Director / Officer | F-InKind | D | Common Stock | 19,192 | 6.25 | 120.0K | 1,742,363 | — | ↗ |
| 2020-08-26 | LIGAND PHARMACEUTICALS INC | 10% Owner | S-Sale | D | Common Stock | 148,700 | 8.11 | 1.21M | 5,819,383 | — | ↗ |
| 2020-08-25 | LIGAND PHARMACEUTICALS INC | 10% Owner | S-Sale | D | Common Stock | 70,000 | 8.02 | 561.6K | 5,968,083 | — | ↗ |
| 2020-07-31 | ZANTE GREG | Officer | — | D | Stock Option (Right to Buy) | 42,000 | 7.69 | 323.0K | 0 | — | ↗ |
| 2020-07-31 | Mancini Marianna | Officer | — | D | Stock Option (Right to Buy) | 10,000 | 7.69 | 76.9K | 0 | — | ↗ |
| 2020-06-30 | FOEHR MATTHEW W | Director | S-Sale | D | Common Stock, par value $0.00001 per share | 13,000 | 7.35 | 95.6K | 26,250 | — | ↗ |
| 2020-03-31 | MORNEAU MICHAEL | Officer | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.68 | 70.2K | 15,000 | — | ↗ |
| 2020-01-19 | MORNEAU MICHAEL | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 2,044 | 7.18 | 14.7K | 92,840 | — | ↗ |
| 2020-01-19 | Lian Brian | Director / Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 3,195 | 7.18 | 22.9K | 1,704,312 | — | ↗ |
| 2020-01-15 | ZANTE GREG | Officer | — | D | Stock Option (Right to Buy) | 32,000 | 8.52 | 272.6K | 0 | — | ↗ |
| 2020-01-15 | Mancini Marianna | Officer | — | D | Stock Option (Right to Buy) | 23,100 | 8.52 | 196.8K | 0 | — | ↗ |
| 2020-01-03 | MORNEAU MICHAEL | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 7.77 | 310.8K | 40,000 | — | ↗ |
| 2020-01-03 | Lian Brian | Director / Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 6,782 | 7.77 | 52.7K | 1,707,507 | — | ↗ |
| 2020-01-02 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 7.95 | 174.9K | 22,000 | — | ↗ |
| 2020-01-02 | SINGLETON J MATTHEW | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 7.95 | 174.9K | 22,000 | — | ↗ |
| 2020-01-02 | Rowland Charles A Jr | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 7.95 | 174.9K | 22,000 | — | ↗ |
| 2020-01-02 | Rouan Sarah Kathryn | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 7.95 | 174.9K | 22,000 | — | ↗ |
| 2020-01-02 | MACARTNEY LAWSON | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 7.95 | 174.9K | 22,000 | — | ↗ |
| 2020-01-02 | FOEHR MATTHEW W | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 7.95 | 174.9K | 22,000 | — | ↗ |
| 2019-10-31 | MORNEAU MICHAEL | Officer | A-Award | A | Stock Option (Right to Buy) | 2,500 | 6.47 | 16.2K | 2,500 | — | ↗ |
| 2019-07-31 | MORNEAU MICHAEL | Officer | A-Award | A | Stock Option (Right to Buy) | 7,500 | 7.69 | 57.7K | 7,500 | — | ↗ |
| 2019-07-01 | Rouan Sarah Kathryn | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 8.32 | 457.6K | 55,000 | — | ↗ |
| 2019-03-30 | Mancini Marianna | Officer | — | D | Stock Option (Right to Buy) | 30,000 | 4.37 | 131.1K | 0 | — | ↗ |
| 2019-01-19 | Mancini Marianna | Officer | — | D | Stock Option (Right to Buy) | 24,500 | 4.65 | 113.9K | 0 | — | ↗ |
| 2019-01-19 | MORNEAU MICHAEL | Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 2,044 | 8.78 | 17.9K | 91,991 | — | ↗ |
| 2019-01-19 | Lian Brian | Director / Officer | F-InKind | D | Common Stock, par value $0.00001 per share | 4,333 | 8.78 | 38.0K | 1,560,152 | — | ↗ |
| 2019-01-03 | Masamune Hiroko | Officer | A-Award | A | Stock Option (Right to Buy) | 66,000 | 7.58 | 500.3K | 66,000 | — | ↗ |
| 2019-01-03 | MORNEAU MICHAEL | Officer | A-Award | A | Stock Option (Right to Buy) | 29,000 | 7.58 | 219.8K | 29,000 | — | ↗ |
| 2019-01-03 | Lian Brian | Director / Officer | A-Award | A | Common Stock, par value $0.00001 per share | 80,897 | 0.00 | — | 1,564,485 | — | ↗ |
| 2019-01-02 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 8.32 | 183.0K | 22,000 | — | ↗ |
| 2019-01-02 | SINGLETON J MATTHEW | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 8.32 | 183.0K | 22,000 | — | ↗ |
| 2019-01-02 | Rowland Charles A Jr | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 8.32 | 183.0K | 22,000 | — | ↗ |
| 2019-01-02 | MACARTNEY LAWSON | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 8.32 | 183.0K | 22,000 | — | ↗ |
| 2019-01-02 | FOEHR MATTHEW W | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 8.32 | 183.0K | 22,000 | — | ↗ |
| 2018-09-25 | LIGAND PHARMACEUTICALS INC | 10% Owner | S-Sale | D | Common Stock | 262,881 | 19.15 | 5.03M | 6,038,083 | — | ↗ |
| 2018-08-31 | ZANTE GREG | Officer | — | D | Stock Option (Right to Buy) | 7,500 | 13.07 | 98.0K | 0 | — | ↗ |
| 2018-08-31 | Mancini Marianna | Officer | — | D | Stock Option (Right to Buy) | 10,000 | 1.04 | 10.4K | 0 | — | ↗ |
| 2018-07-01 | Masamune Hiroko | Officer | — | D | Common Stock, par value $0.00001 per share | 0 | 0.00 | — | 96,197 | — | ↗ |
| 2018-06-30 | Mancini Marianna | Officer | — | D | Stock Option (Right to Buy) | 15,000 | 1.08 | 16.2K | 0 | — | ↗ |
| 2018-05-31 | SINGLETON J MATTHEW | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 9,500 | 9.82 | 93.3K | 9,500 | — | ↗ |
| 2018-05-31 | MORNEAU MICHAEL | Officer | S-Sale | D | Common Stock, par value $0.00001 per share | 21,551 | 9.25 | 199.3K | 94,035 | — | ↗ |
| 2018-05-29 | Webster Stephen W | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 8,000 | 5.21 | 41.7K | 8,000 | — | ↗ |
| 2018-05-29 | Rowland Charles A Jr | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 30,000 | 5.16 | 154.8K | 30,000 | — | ↗ |
| 2018-05-29 | MACARTNEY LAWSON | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 47,965 | 5.22 | 250.3K | 47,965 | — | ↗ |
| 2018-05-21 | LIGAND PHARMACEUTICALS INC | 10% Owner | J-Other | D | Convertible Note (convertible into Common Stock) | 1,916,509 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
115.89M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Brian Lian, Ph.D. Chief Executive Officer | 672.0K | — | 17.76M | 2.47M | 373.0K | — | 21.27M | 95.09% | ↗ |
| 2 | 2025 | Marianne Mancini Chief Operating Officer | 540.0K | — | 3.23M | 1.17M | 225.0K | — | 5.16M | 85.18% | ↗ |
| 3 | 2025 | Greg Zante Chief Financial Officer | 521.0K | — | 3.23M | 1.17M | 217.0K | — | 5.14M | 85.63% | ↗ |
| 4 | 2024 | Brian Lian, Ph.D. Chief Executive Officer | 640.0K | — | 8.47M | 4.64M | 440.0K | 113.7K | 14.30M | 91.65% | ↗ |
| 5 | 2024 | Brian Lian, Ph.D. Chief Executive Officer | 640.0K | — | 8.47M | 4.64M | 440.0K | 113.7K | 14.30M | 91.65% | ↗ |
| 6 | 2024 | Marianne Mancini Chief | 490.0K | — | 1.97M | 2.00M | 245.0K | — | 4.70M | 84.37% | ↗ |
| 7 | 2024 | Marianne Mancini Chief Operating Officer | 490.0K | — | 1.97M | 2.00M | 245.0K | — | 4.70M | 84.37% | ↗ |
| 8 | 2024 | Greg Zante Chief Financial Officer | 475.0K | — | 1.97M | 2.00M | 238.0K | — | 4.68M | 84.77% | ↗ |
| 9 | 2023 | Brian Lian, Ph.D. Chief Executive Officer | 615.0K | — | 7.94M | 3.70M | 372.1K | — | 12.63M | 92.18% | ↗ |
| 10 | 2023 | Marianne Mancini Chief Operating Officer | 465.0K | — | 1.58M | 1.26M | 205.0K | — | 3.51M | 80.92% | ↗ |
| 11 | 2023 | Marianne Mancini Chief | 465.0K | — | 1.58M | 1.26M | 205.0K | — | 3.51M | 80.92% | ↗ |
| 12 | 2023 | Greg Zante Chief Financial Officer | 455.0K | — | 1.58M | 1.26M | 200.0K | — | 3.50M | 81.26% | ↗ |
| 13 | 2022 | Brian Lian, Ph.D. Chief Executive Officer | 611.8K | — | 3.04M | 1.40M | 353.3K | — | 5.41M | 82.16% | ↗ |
| 14 | 2022 | Brian Lian, Ph.D. Chief Executive Officer | 611.8K | — | 3.04M | 1.40M | 353.3K | — | 5.41M | 82.16% | ↗ |
| 15 | 2022 | Marianne Mancini Chief | 446.0K | — | 792.2K | 626.5K | 187.3K | — | 2.05M | 69.14% | ↗ |
| 16 | 2022 | Marianne Mancini Chief Operating Officer | 446.0K | — | 792.2K | 626.5K | 187.3K | — | 2.05M | 69.14% | ↗ |
| 17 | 2022 | Greg Zante Chief Financial Officer | 425.0K | — | 675.1K | 432.1K | 178.5K | — | 1.71M | 64.72% | ↗ |
| 18 | 2021 | Brian Lian, Ph.D. Chief Executive Officer | 594.0K | — | 1.66M | 1.52M | 278.0K | — | 4.06M | 78.52% | ↗ |
| 19 | 2021 | Marianne Mancini Chief Operating Officer | 405.0K | — | 597.4K | 367.2K | 138.0K | — | 1.51M | 63.98% | ↗ |
| 20 | 2021 | Marianne Mancini Chief Operating Officer | 405.0K | — | 597.4K | 367.2K | 138.0K | — | 1.51M | 63.98% | ↗ |
| 21 | 2021 | Greg Zante Chief Financial Officer | 400.0K | — | 491.1K | 318.3K | 136.0K | — | 1.35M | 60.16% | ↗ |
| 22 | 2021 | Greg Zante Chief Financial Officer | 400.0K | — | 491.1K | 318.3K | 136.0K | — | 1.35M | 60.16% | ↗ |
| 23 | 2020 | Brian Lian, Ph.D. Chief Executive Officer | 577.0K | — | 2.49M | 1.82M | 301.0K | — | 5.19M | 83.07% | ↗ |
| 24 | 2019 | Brian Lian, Ph.D. Chief Executive Officer | 525.0K | — | 1.53M | 1.25M | 210.0K | — | 3.51M | 79.07% | ↗ |
| 25 | 2019 | Hiroko Masamune, Ph.D. Former Chief Development Officer | 233.3K | — | 323.4K | 349.3K | — | — | 906.1K | 74.25% | ↗ |
| 26 | 2018 | Brian Lian, Ph.D. Chief Executive Officer | 485.0K | — | 186.0K | 465.3K | 267.0K | — | 1.40M | 46.41% | ↗ |
| 27 | 2018 | Hiroko Masamune, Ph.D. Former Chief Development Officer | 302.7K | — | 188.9K | 395.3K | 106.0K | — | 992.9K | 58.84% | ↗ |
| 28 | 2018 | Hiroko Masamune, Ph.D. Chief Development Officer | 302.7K | — | 188.9K | 395.3K | 106.0K | — | 992.9K | 58.84% | ↗ |
| 29 | 2018 | Michael Morneau Former Chief Financial Officer | 285.3K | — | 69.8K | 174.5K | 90.0K | — | 619.6K | 39.42% | ↗ |
| 30 | 2017 | Brian Lian, Ph.D. Chief Executive Officer | 440.0K | — | — | 254.7K | 110.0K | — | 804.7K | 31.65% | ↗ |
| 31 | 2017 | Michael Morneau Former Chief Financial Officer | 300.0K | — | — | 100.4K | 52.5K | — | 452.9K | 22.16% | ↗ |
| 32 | 2016 | Brian Lian, Ph.D. Chief Executive Officer | 400.0K | — | — | 256.9K | 100.0K | — | 756.9K | 33.95% | ↗ |
| 33 | 2016 | Michael Morneau Chief Financial Officer | 285.0K | — | — | 85.3K | 63.0K | — | 433.3K | 19.69% | ↗ |
| 34 | 2016 | Michael Morneau Former Chief Financial Officer | 285.0K | — | — | 85.3K | 63.0K | — | 433.3K | 19.69% | ↗ |
| 35 | 2016 | Rochelle Hanley, M.D. Former Chief Medical Officer | 80.0K | — | — | 53.8K | — | — | 133.8K | 40.20% | ↗ |
| 36 | 2015 | Brian Lian, Ph.D. Chief Executive Officer | 321.2K | — | 1.10M | 613.2K | 139.1K | 14.0K | 2.19M | 78.30% | ↗ |
| 37 | 2015 | Michael Dinerman, M.D. Former Chief Operating Officer | 173.9K | — | 1.19M | 315.4K | — | 74.5K | 1.75M | 85.82% | ↗ |
| 38 | 2015 | Michael Morneau Chief Financial Officer | 225.0K | — | 799.9K | 178.7K | 72.9K | — | 1.28M | 76.66% | ↗ |
| 39 | 2015 | Rochelle Hanley, M.D. Former Chief Medical Officer | 147.9K | — | 796.9K | 210.2K | 51.4K | — | 1.21M | 83.48% | ↗ |
| 40 | 2015 | Rochelle Hanley, M.D. Former Chief Medical Officer | 147.9K | — | 796.9K | 210.2K | 51.4K | — | 1.21M | 83.48% | ↗ |
| 41 | 2014 | Brian Lian, Ph.D. Chief Executive Officer | 164.4K | 45.1K | 168.1K | — | — | — | 377.6K | 44.53% | ↗ |
| 42 | 2014 | Michael Dinerman, M.D. Former Chief Operating Officer | 139.7K | 27.8K | — | — | — | 2.9K | 170.5K | 0.00% | ↗ |
| 43 | 2014 | Michael Morneau Chief Financial Officer | 102.6K | 26.8K | — | — | — | 25.6K | 155.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian Lian | President, Chief Executive Officer & Director | 1M | — |
| Marianne Mancini | Chief Operating Officer | 765.0K | female |
| Gregory S. Zante | Chief Financial Officer | 738.0K | male |
| Michael Morneau | Vice President of Finance & Administration | 375.3K | male |
| Neil Aubuchon | Chief Commercial Officer | — | male |
| Nils U. Olsson | Senior Vice President of Technical Operations | — | — |
| Geoffrey E. Barker | Chief Development Officer | — | — |
| Katherine Mercier | Vice President of Quality and Compliance | — | female |
| Kenneth Herman | Senior Vice President of Commercial, Marketing & Sales | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VKTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
